
| To: | |
|------------|----------------|
| Commission | er for Patents |
| Box R€E, | • |
| Washington | DC 20231 |







provides for continued examination of an utility or plant application filed on or after June 8, 1995.

See The American Inventors Protection Act of 1999 (AIPA).

| | • |
|------------------------|-----------------|
| Application Number | 09/125,114 |
| Filing Date | August 18, 1998 |
| First Named Inventor | PRICE |
| Group Art Unit | 1615 |
| Examiner Name | Berman, A. |
| Attorney Docket Number | 108129-08004 |

NOTE: 37 C.F.R. § 1.114 is effective on May 29, 2000. If the above-identified application was filed prior to May 29, 2000,

This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above-identified application.

| | applicant may wish to continue filing a continued prosecution application (CPA) under 37 C.F.R. § 1.53 (d) (PTO/SB/29) instead of a RCE to be eligible for the patent term adjustment provisions of the AIPA. See Changes to Application Examination and Provisional Application Practice, Interim Rule, 65 Fed. Reg. 14865 (Mar. 20, 2000), 1233 Off. Gaz. Pat. Office 47 (Apr. 11, 200 PA) which established RCE practice. | EIV |
|-------|--|-----|
| 1. | Submission required under 37 C.F.R. 1.114 a. Previously submitted i. Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on (Any unentered amendment(s) referred to above will be entered). | |
| | ii. Consider the arguments in the Appeal Brief or Reply Brief previously filed oniii. \textbf{X} Other Information Disclosure Statement filed on March 9, 2000_ | |
| | b. Enclosed i. Request For Reconsideration Of Information Disclosure Statement ii. Affidavit(s)/Declaration(s) iii. Information Disclosure Statement (IDS) iv. Other: Petition for Extension of Time | |
| 2. | Miscellaneous a. Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103(c) for a period of months. (Period of suspension shall not exceed 3 months; Fee under 37 C.F.R. § 1.17(i) required) b. Other | |
| 3. | Fees The RCE fee under 37 C.F.R. § 1.17(e) is required by 376 C.F.R. § 1.114 when the RCE is filed. a. The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No01-2300 | |
| | i. RCE fee required under 37 C.F.R. § 1.17(e) ii. Extension of time fee (37 C.F.R. §§ 1.136 and 1.17) iii. Other b. Check in the amount of \$710.00 c. Payment by credit card (Form PTO-2038 enclosed) | |
| 7 | SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED | |
| ļ | Name (Print) King L. Wong Registration No. (Attorney) 37,500 | |
| 00 SI | Signature King L. Wong Date December 12, 2000 | |
| | | |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

PRICE

For:

Serial No.: 09/125,114

Filed: August 18, 1998

DEC 1 2 2000 LES

Group Art Unit: 1615

Examiner: Berman, A.

#-15 840 12.27.11)

DOSAGE FORM OF IBUPROFEN RECEIVED

REQUEST FOR RECONSIDERATION OF INFORMATION DISCLOSURE STATEMENT

DEC 14 2000

Assistant Commissioner for Patents Washington, D.C. 20231

December 12, 2000

TECH CENTER 1600/2900

Sir:

This paper accompanies a Request for Continued Examination filed on December 12, 2000. Along with this paper, a Petition for Extension of Time is filed to extend the response due date to the Office Action mailed June 15, 2000 three months from September 15, 2000 to December 15, 2000.

The Office Action asserts that two references, i.e. Hannula et al., Eur. J. Drug Metab. Pharmacokinetics 1991, Special Issue III, pp. 221-227; and British Pharmacopoeia 1993, pages 601, 603 and 604, cited in the IDS filed on March 9, 2000 did not conform with the requirement of specifying publication dates. However, the Hannula reference and the British Pharmacopoeia reference were listed in the IDS as published in 1991 and 1993, respectively. Since the publication dates of these two references were already disclosed in the IDS filed on March 9, 2000, applicant informed the Examiner of this fact via the telephone on October 30, 2000. The Examiner promised in the telephone interview that she would consider these two references. Applicant now officially requests that the two references be considered and that the Examiner place her initials adjacent to the

appropriate citations in the IDS.

In the event that this paper or the Request for Continued Examiner is not deemed timely filed, applicant hereby petitions for an appropriate extension of time. Should any fees be due with respect to this paper, please charge Counsel's Deposit Account No. 01-2300.

Respectfully submitted, ARENT FOX KINTNER PLOTKIN & KAHN, PLLC

King L. Wong

Attorney for Applicant Reg. No. 37,500

Atty. Docket No. 108129-08004 1050 Connecticut Avenue, NW Suite 600 Washington, DC 20036-5339

Tel: (202) 857-8954